Events

Senior Research Scientist Shanon Ranjit from the Garvan Institute of Medical Research has been named the winner of the Early-Stage Innovation Forum (2025, held as part of the AusMedtech conference in Sydney.

AusBiotech has shared the latest release of Australasian Biotechnology during the biggest week in Australian medtech.

AusBiotech CEO Rebekah Cassidy and Bellberry's Kylie Sproston spoke at the BioPharmaDispatch conference about Australia's strengths as a location for the life sciences sector and the opportunities to attract more.

Lumos Diagnostics (ASX:LDX) has received confirmation of Medicare reimbursement coverage from an additional Medicare Administrative Contractor, CGS Administrators. 

Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has announced that the first patient has been dosed in its Phase 2a clinical study of PTX-100.

Atomo Diagnostics (ASX:AT1) has secured another purchase order from the National Association of People with HIV Australia for approximately $450,000 worth of HIV Self-Tests.

Immutep (ASX:IMM) has announced that the investigator-initiated EFTISARC-NEO Phase 2 trial evaluating its eftilagimod alpha with radiotherapy plus MSD's KEYTRUDA (pembrolizumab) in the neoadjuvant setting for resectable soft tissue sarcoma has met its primary endpoint.

BlinkLab (ASX:BB1) has announced the commencement of the main study phase of its pivotal US-based FDA 510(k) diagnostic trial for its smartphone-based autism diagnostic tool, with the engagement of a significant new clinical site.

Chimeric Therapeutics (ASX:CHM) has announced that the CHM CDH17 clinical trial has advanced to Dose Level 2, following the observation of no safety concerns or off-target effects at Dose Level 1.

Argenica managing director Dr Liz Dallimore said, “Our new divisional US patent further strengthens Argenica’s already wide-ranging protection for neuroprotective peptides."

Zelira Therapeutics (ASX:ZLD) has announced the publication of its clinical study report, which evaluated its ZLT-L-007 in 60 adults diagnosed with diabetic neuropathy.

Dimerix (ASX:DXB) has confirmed that the Independent Data Monitoring Committee successfully concluded a sixth review of the ACTION3 phase 3 clinical trial safety data.